article · Frontiers in Digital Health
Research into rare diseases is heavily constrained by small patient populations, stringent privacy rules, and an urgent demand for diverse datasets to build artificial intelligence tools for diagnosis and therapy. Synthetic data, which consists of artificially generated datasets that mirror patient attributes whilst safeguarding personal confidentiality, offers a practical way to overcome these data shortages. Evidence from case studies demonstrates that synthetic datasets can accurately replicate real patient characteristics, support predictive modelling, and ensure adherence to international privacy standards such as GDPR and HIPAA. In addition, these artificial datasets facilitate clinical trial simulations, artificial intelligence model training, and cross-border research collaborations. Although current technical limitations persist, synthetic data generation significantly enhances data accessibility, creating new opportunities to accelerate the global diagnosis, management, and treatment of rare medical conditions.
Rare diseases affect relatively few individuals, making it difficult to gather enough medical information to build effective diagnostic tools. By generating privacy-compliant artificial data that mimics real health records, researchers can safely share information across borders and train healthcare algorithms without compromising patient confidentiality, ultimately speeding up the development of targeted therapies.
The work enables the development of artificial intelligence diagnostics, therapy discovery, and simulated clinical trials. Likely adopters include healthcare software developers, pharmaceutical organisations, and clinical researchers requiring regulatory-compliant datasets under GDPR and HIPAA. Because the findings rely on case studies while noting ongoing limitations, the approach is applied and tested in specific contexts rather than being an off-the-shelf product ready for widespread commercial rollout.
AI-generated from the published abstract. Always read the original work before citing.
Rare disease research faces significant challenges due to limited patient data, strict privacy regulations, and the need for diverse datasets to develop accurate AI-driven diagnostics and treatments. Synthetic data-artificially generated datasets that mimic patient data while preserving privacy-offer a promising solution to these issues. This article explores how synthetic data can bridge data gaps, enabling the training of AI models, simulating clinical trials, and facilitating cross-border collaborations in rare disease research. We examine case studies where synthetic data successfully replicated patient characteristics, and supported predictive modelling and ensured compliance with regulations like GDPR and HIPAA. While acknowledging current limitations, we discuss synthetic data's potential to revolutionise rare disease research by enhancing data availability and privacy file enabling more efficient and effective research efforts in diagnosing, treating, and managing rare diseases globally.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3389/fdgth.2025.1563991
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
